Both an Open Label Extension (OLEX) study and an Expanded Access Program (EAP) can be used to provide continued treatment access after phase 3 clinical trials have ended. In some cases, an OLEX study would be the appropriate choice. However, in others, an EAP can be used as a time- and cost-effective alternative.
To help companies understand both programs and consider which would be the best option for their post-phase 3 efforts, WEP Clinical has created useful table outlining the main differences between an OLEX study and an EAP. Please complete the form below to download the resource.